Author/Authors :
Natalya A. Smirnova، نويسنده , , Ilay Rakhman، نويسنده , , Natalia Moroz، نويسنده , , Manuela Basso، نويسنده , , Jimmy Payappilly، نويسنده , , Sergey Kazakov، نويسنده , , Francisco Hernandez-Guzman، نويسنده , , Irina N. Gaisina، نويسنده , , Alan P. Kozikowski، نويسنده , , Rajiv R. Ratan، نويسنده , , Irina G. Gazaryan، نويسنده ,
Abstract :
Small molecules inhibiting hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs) are the focus of drug development efforts directed toward the treatment of ischemia and metabolic imbalance. A cell-based reporter produced by fusing HIF-1α oxygen degradable domain (ODD) to luciferase was shown to work as a capture assay monitoring stability of the overexpressed luciferase-labeled HIF PHD substrate under conditions more physiological than in vitro test tubes. High throughput screening identified novel catechol and oxyquinoline pharmacophores with a “branching motif” immediately adjacent to a Fe-binding motif that fits selectively into the HIF PHD active site in in silico models. In accord with their structure-activity relationship in the primary screen, the best “hits” stabilize HIF1α, upregulate known HIF target genes in a human neuronal line, and exert neuroprotective effects in established model of oxidative stress in cortical neurons.